CIRM Quick Links
Right Column
Notice of Proposed Amendment to Expand Scope of Item 9 and Proposed Additional Item for
INDEPENDENT CITIZENS OVERSIGHT COMMITTEE ("ICOC")
TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE (CIRM)
Organized Pursuant To Government Code section 11346.5(a)(17)
and
The
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
Date: Tuesday, August 12, 2008
Time: 4:30 PM – 9:30 PM (Estimated)
Date: Wednesday, August 13, 2008
Time: 9:30 AM – 5:00 PM (Estimated)
Location:
- Stanford University
Arrillaga Alumni Center
McCaw Hall
326 Galvez Street
Stanford, CA 94305
Open Session
- Proposed amendment to item 9 so it would read as follows:
Consideration of update from Standards Working Group and regulatory amendments authorizing a procedure for petitioning the ICOC to designate stem cell lines derived before November 2006 as acceptably derived for use in CIRM-funded research, and to govern use of embryos created for reproductive purposes before August 13, 2008.
- Proposed new item: Consideration of eligibility criteria in concept plan for Translational 1 RFA.
THE ORDER OF BUSINESS MAY BE CHANGED WITHOUT NOTICE.
Notice is hereby given that the order of consideration of matters on this agenda may be changed without prior notice.
**NOTICE**
The California Institute for Regenerative Medicine and its Independent Citizens Oversight Committee, and any subcommittees thereof, comply with the Americans with Disabilities Act (ADA) by ensuring that the meeting facilities are accessible to persons with disabilities, and providing that this notice and information given to the Members of the Committee is available to the public in appropriate alternative formats when requested. If you need further assistance, including disability-related modifications or accommodations, you may contact Melissa King at the California Institute for Regenerative Medicine at 415-396-9100 no later than the day prior to the meeting.
Questions or requests for additional information prior to the Independent Citizens Oversight Committee meeting may be referred to Melissa King at the California Institute for Regenerative Medicine at mking@cirm.ca.gov or 415-396-9100.
This meeting agenda is also available on the website for the California Institute for Regenerative Medicine at http://www.cirm.ca.gov.

